PROMIS NEUROSCIENC (OTCMKTS:ARFXF) is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s Disease.
Shares of ARFXF have gotten a boost following some recent positive clinical results which suggest that ProMIS’s beta-directed antibody treatment for Alzheimer’s patients may be safer than existing solutions. It gave rise to an awakening on the chart earlier this month, and this week the PPS continued to press to new highs.
Shortly following the New Year, PROMIS NEUROSCIENC (OTCMKTS:ARFXF) announced that its lead product candidate for Alzheimer’s disease, PMN310, showed absence of binding to amyloid beta (AB) plaque in and around blood vessels in Alzheimer’s brain samples in a preclinical study directly comparing PMN310 to other AB-directed antibodies. Binding of therapeutic antibodies to AB deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients.
Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “PMN310 was designed to selectively target the toxic, prion-like AB oligomers, now widely believed to be a root cause of Alzheimer’s. By not targeting AB plaque, especially in and around blood vessels in the brain, we anticipate PMN310 may not be associated with the dose-limiting brain swelling seen with plaque-binding antibody therapeutics like aducanumab. Confirmation of such an improved safety profile in clinical trials would allow for administration of higher doses to Alzheimer’s patients, thereby leading to greater therapeutic potency of PMN310.”
The binding profile of PMN310 in human Alzheimer’s disease brain tissue, as well as in brain samples from a mouse Alzheimer’s model, was directly compared to that of other AB-directed antibodies in a preclinical study using the technique of immunohistochemistry (IHC). IHC is the process of selectively imaging antigens (e.g. proteins) in cells of a tissue section by exploiting the principle of antibodies (such as PMN310, aducanumab) binding specifically to their antigen targets in biological tissues.
Results of the study showed binding of aducanumab and bapineuzumab to AB plaque throughout the brain tissue, including in and around the blood vessels. Conversely, binding of PMN310 to AB plaque was not observed in any region of the Alzheimer’s brain tissues.
Prior clinical studies have shown that treatment with antibodies targeting AB plaque, like bapineuzumab (Johnson & Johnson) and aducanumab (Biogen), are associated with dose-limiting brain swelling and/or microhemorrhages in a significant number of Alzheimer’s patients. Aducanumab appears to target both AB plaque and toxic prion-like AB oligomers, the latter now considered by many experts in the field to be the key therapeutic target.
ProMIS has shown in multiple preclinical studies that PMN310 has the advantage of selectively targeting toxic prion-like AB oligomers, with no “off-target” binding to AB plaque, potentially allowing for the safe administration of higher effective doses of PMN310 compared to aducanumab. (Source: (PR Newswire)
So in addition to having promising studies underway on a lead candidate which may be able to have a competitive advantage over top name Alzheimer’s drugs by way of being safer to administer. It’s wonder that shares of ARFXF have shot up to their highest PPS since July. We’ll continue to track its activity going forward. Stay locked to Street Register for updates, and we’ll deliver important developments on ARFXF as they unfold. In the meantime, be sure you’re signed up for our 100% free smallcap newsletter for more great content. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in ARFXF stock, short or long.